Private equity firm BC Partners is now considering the sale of European generic drugmaker Pharmathen estimated at $1.8 billion, according to a report.
- BC Partners is speaking with potential advisers and now looking at the options for the business according to people familiar with the matter who chose to remain unidentified due citing confidentiality. It acquired Pharmathen from the founding family for 475 million euros in 2015.
- Deliberations are currently ongoing and BC Partners could decide to keep the manufacturer but no confirmations have been made by representatives of both parties.
- Pharmathen develops and manufactures generic drugs that can be administered via tablets, drops, and injection. It ended 2020 with over 30 products lined up for launch with a focus on the US market.
- BC Partners is in the middle of an 8.5-billion euro fund raising for its next flagship buyout fund with investor capital collection targeted to be finished this year.
- Healthcare-related deals in Europe are estimated at $24.5 billion so far this year according to Bloomberg data, up 400% from the comparable period in 2020.
